<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847974</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-010</org_study_id>
    <nct_id>NCT03847974</nct_id>
  </id_info>
  <brief_title>Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003</brief_title>
  <official_title>Open-Label Extension, Phase 2b Study to Evaluate the Longer Term Efficacy and Safety of LIB003 in Patients on Stable Lipid Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of&#xD;
      additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the longer term safety, tolerability, immunogenicity, PK, PD and LDL C lowering&#xD;
      efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing&#xD;
      every 4 weeks (Q4W) in patients on stable maximally tolerated statins with or without&#xD;
      ezetimibe who completed the phase 2 dose ranging trial LIB003-002&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>52 weeks</time_frame>
    <description>safety and tolerability will be based on the incidence and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in serum LDL-C from baseline after 52 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIB003</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIB003</intervention_name>
    <description>300 mg SC Q4W</description>
    <arm_group_label>LIB003</arm_group_label>
    <other_name>lerodalcibep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. men and women 18 years or older&#xD;
&#xD;
          2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic&#xD;
             cardiovascular disease (CVD) event or evidence of CVD or without CVD but at high risk&#xD;
             for CVD based on American Heart Association/American College of Cardiology (AHA/ACC)&#xD;
             CVD risk calculator, or aged 40 years and older with diabetes and moderate- to&#xD;
             high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous&#xD;
             familial hypercholesterolemia (HeFH)&#xD;
&#xD;
          3. patients who met original entry criteria in, and completed, the double-blind,&#xD;
             placebo-controlled 16-week Phase 2 study (LIB003-002)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients who did not who complete the double-blind, placebo-controlled 16-week Phase 2&#xD;
             study (LIB003-002)&#xD;
&#xD;
          2. &lt;18 years of age&#xD;
&#xD;
          3. pregnant or women of childbearing potential not using acceptable birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

